Sunday, 20 September 2026European Markets

Selloff Continues: PIERRE VAC Shares Down 31% In Last 10 Sessions

Loading stream...

(vianews) - investors of pierre vac bsa cre (vacbt.pa) are taking a beating as its shares dipped 31.82% over 10 sessions, from eur0.44 to eur0.30 at 15:27 est on friday - this marks five consecutive sessions of losses for this cac 40 company listed under vacbt.pa's ticker symbol vacbt.pa; while overall cac 40 index rose by 0.22% to eur7,326.80 vacbt.pa still struggled; its closing price of eur0.30 represents a 16.67% drop from its 52 week high of eur0.36

yearly analysis

pierre vac bsa cre is currently trading below its 52-week low of eur0.30 and this suggests that its stock has been underperforming over the past year. while this trend may continue for now, investors must carefully evaluate other factors like company financials, industry outlook and overall market conditions before making investment decisions. it is highly advised to conduct an analysis as well as seek professional guidance before investing.

more news about pierre vac bsa cre (vacbt.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,982
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,982 facts checked against source5,299 source documents archived
Query this data → isubstrate.com